With the aging of society and the emergence of stress events (such as the COVID-19 pandemic), the prevalence of psychiatric diseases, such as anxiety and depression remain increased, which has become an increasing challenge for public health. Cognitive impairment is one of the common symptoms of these diseases. Previous studies found that after appropriate treatment, even if the mental symptoms are relieved, cognitive impairment still exists. In addition, there is still no reliable treatment for cognitive impairment in elderly patients with mental disorders. These findings suggest that the pathogenesis of cognitive impairment is not completely consistent with that of psychiatric diseases, and its molecular mechanisms need to be further clarified.
This Research Topic will focus on the potential molecular mechanisms of cognitive impairment in psychiatric diseases, and further investigate the prediction, prevention, and treatment strategy of cognitive impairment from a molecular perspective as well as the identification of potential biomarkers for cognitive impairment. Deciphering such questions will not only provide insights into basic neurosciences but also facilitate clinical applications of psychiatric diseases related to cognitive impairment.
This Research Topic is focused on presenting basic, preclinical, and clinical research that includes molecular aspects that potentially contribute to the diagnosis, prevention, and treatment of cognitive impairment in psychiatric diseases. We encourage contributors to submit Original Research, Brief Research Report, Review, Systematic Review, and Mini-Review articles that contribute to the potential molecular mechanism both in central and peripheral aspects, including but not limited to:
• Findings for important molecular pathways involved in psychiatric diseases with cognitive impairment
• Identification of molecules as potential biomarkers in cognitive impairment
• Consistent or different molecular mechanisms of cognitive impairment in different psychiatric diseases
• New animal models for cognitive impairment
• New treatments such as pharmacotherapy, physical intervention, or psychotherapy with potential application in basic or clinical practice
With the aging of society and the emergence of stress events (such as the COVID-19 pandemic), the prevalence of psychiatric diseases, such as anxiety and depression remain increased, which has become an increasing challenge for public health. Cognitive impairment is one of the common symptoms of these diseases. Previous studies found that after appropriate treatment, even if the mental symptoms are relieved, cognitive impairment still exists. In addition, there is still no reliable treatment for cognitive impairment in elderly patients with mental disorders. These findings suggest that the pathogenesis of cognitive impairment is not completely consistent with that of psychiatric diseases, and its molecular mechanisms need to be further clarified.
This Research Topic will focus on the potential molecular mechanisms of cognitive impairment in psychiatric diseases, and further investigate the prediction, prevention, and treatment strategy of cognitive impairment from a molecular perspective as well as the identification of potential biomarkers for cognitive impairment. Deciphering such questions will not only provide insights into basic neurosciences but also facilitate clinical applications of psychiatric diseases related to cognitive impairment.
This Research Topic is focused on presenting basic, preclinical, and clinical research that includes molecular aspects that potentially contribute to the diagnosis, prevention, and treatment of cognitive impairment in psychiatric diseases. We encourage contributors to submit Original Research, Brief Research Report, Review, Systematic Review, and Mini-Review articles that contribute to the potential molecular mechanism both in central and peripheral aspects, including but not limited to:
• Findings for important molecular pathways involved in psychiatric diseases with cognitive impairment
• Identification of molecules as potential biomarkers in cognitive impairment
• Consistent or different molecular mechanisms of cognitive impairment in different psychiatric diseases
• New animal models for cognitive impairment
• New treatments such as pharmacotherapy, physical intervention, or psychotherapy with potential application in basic or clinical practice
![Chemogenetic inhibition of the AIC-BLA circuit disrupts stress-induced abnormal changes in decision-making behavior. (A) Diagrammatic representation of the expression of hM4Di-mCherry in the AIC. (B) c-Fos expression after CNO treatment in the AIC of hM4Di-overexpressed mice (scale bar: 50 μm). (C) Effect of AIC inhibition on stress leads to aberrant decision-making behavior. Repeated-measures ANOVA with Bonferroni correction, F(3,28) = 182.3; *P < 0.05 vs. L-L stress/vehicle group (post-hoc Tukey’s test, P = 0.0475 on day 6, P = 0.0087 on day 8, P = 0.0495 on day 11, P = 0.0370 on day 12 P = 0.0191 on day 14), #P < 0.05 vs. H-H stress/vehicle group (post-hoc Tukey’s test, P = 0.0078 on day 8, P = 0.0126 on day 11, P = 0.0152 on day 14), n = 8. (D) Effect on the number of entries into empty arms (F(1,14) = 0.1889, P = 0.6705). (E) Schematic representation of the anterograde virus injection strategy. AIC-projecting neurons were found mainly in the basolateral amygdala (BLA). (F) Schematic picture of selective labeling of BLA neurons innervated by AIC projection. (G) Selectively inhibiting the AIC-BLA circuit can reduce risk-taking behavior of mice. Repeated ANOVA revealed significant effects on treatment [F(1,10) = 57.86, P < 0.05, n = 6] *P < 0.05 vs. L-L stress/vehicle group (post-hoc Tukey’s test, P = 0.0041 on day 5, P = 0.0094 on day 6, P = 0.0338 on day 7, P = 0.0001 on day 10, P = 0.0366 on day 11, P = 0.0097 on day 13), #P < 0.05 vs. H-H stress/vehicle group (post-hoc Tukey’s test, P = 0.0201 on day 5, P = 0.0003 on day 10, P = 0.0279 on day 13). (H) Effect on the number of entries into empty arms (F(1,10) = 1.668, P = 0.2256).](https://www.frontiersin.org/_rtmag/_next/image?url=https%3A%2F%2Fwww.frontiersin.org%2Ffiles%2FArticles%2F1094808%2Ffncel-17-1094808-HTML%2Fimage_m%2Ffncel-17-1094808-g003.jpg&w=3840&q=75)
